THC and Ketamine Effects in Humans
common.study.values.description
“THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis”
The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects, and characterize the interactive effects of ketamine and THC on various electrophysiological (EEG), cognitive, and behavioral outcomes.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - Active Delta-9-THC
Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)
Drug - Placebo Delta-9-THC
A placebo dose given intravenously (IV)
Drug - Active Ketamine
Active Ketamine (0.2 mg/kg) given intravenously (IV)
Drug - Placebo Ketamine
A placebo dose given intravenously (IV)
participant.views.study.view.additional
participant.views.study.view.scientific-title
An Electrophysiological Examination of CB1 and NMDA Receptors in Humans
common.study.values.clinical-trial-id
NCT04199468
participant.views.study.view.id
eVOX5a
